These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 31456478)
1. Rapid change of a cohort of 570 unproven stem cell clinics in the USA over 3 years. Knoepfler PS Regen Med; 2019 Aug; 14(8):735-740. PubMed ID: 31456478 [No Abstract] [Full Text] [Related]
2. Texas H.B. 810: Increased Access to Stem Cell Interventions or an Increase in Unproven Treatments? Matthews K; Kunisetty B; Sprung K Stem Cells Dev; 2018 Nov; 27(21):1463-1465. PubMed ID: 30122128 [TBL] [Abstract][Full Text] [Related]
4. Federal Regulatory Oversight of US Clinics Marketing Adipose-Derived Autologous Stem Cell Interventions: Insights From 3 New FDA Draft Guidance Documents. Turner LG Mayo Clin Proc; 2015 May; 90(5):567-71. PubMed ID: 25939934 [No Abstract] [Full Text] [Related]
5. Selling stem cell 'treatments' as research: prospective customer perspectives from crowdfunding campaigns. Snyder J; Turner L Regen Med; 2018 Jun; 13(4):375-384. PubMed ID: 29985757 [TBL] [Abstract][Full Text] [Related]
6. US stem cell clinics, patient safety, and the FDA. Turner L Trends Mol Med; 2015 May; 21(5):271-3. PubMed ID: 25945404 [TBL] [Abstract][Full Text] [Related]
7. Unproven but Profitable: The Boom in US Stem Cell Clinics. Rubin R JAMA; 2018 Oct; 320(14):1421-1423. PubMed ID: 30326510 [No Abstract] [Full Text] [Related]
8. Identity and ownership issues in the regulation of autologous cells. Sipp D Regen Med; 2017 Oct; 12(7):827-838. PubMed ID: 29115180 [TBL] [Abstract][Full Text] [Related]
9. US clinics marketing unproven and unlicensed adipose-derived autologous stem cell interventions. Turner LG Regen Med; 2015 May; 10(4):397-402. PubMed ID: 26022761 [No Abstract] [Full Text] [Related]
10. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions. Turner L Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145 [TBL] [Abstract][Full Text] [Related]
11. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States. Sipp D Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146 [TBL] [Abstract][Full Text] [Related]
12. FDA challenges stem-cell clinic. Cyranoski D Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009 [No Abstract] [Full Text] [Related]
15. From bench to FDA to bedside: US regulatory trends for new stem cell therapies. Knoepfler PS Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841 [TBL] [Abstract][Full Text] [Related]